UFP Technologies, Inc. — FY 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. UFP designs and converts foam, plastics, composites and natural-fiber materials into custom products, principally for medical, automotive, consumer, electronics, industrial, and aerospace and defense markets. The company reports one operating segment.
Financial performance
| Metric | FY 2016 | FY 2015 | Change |
|---|---|---|---|
| Net sales | $146.1 million | $138.9 million | +5.2% |
| Gross profit / margin | $34.7 million / 23.7% | $37.5 million / 27.0% | Margin down 3.3 percentage points |
| Operating income | $12.2 million | $11.7 million | +4.5% |
| Net income | $8.0 million | $7.6 million | +5.0% |
| Diluted EPS | $1.10 | $1.05 | +$0.05 |
| Cash from operations | $9.4 million | $13.1 million | Down $3.7 million |
- FY 2016 operating income included a $2.1 million polyurethane-foam antitrust settlement gain. Restructuring costs were $0.4 million, versus $1.8 million in 2015.
- Cash and cash equivalents were $31.4 million at year-end. Working capital was $60.3 million, up from $52.6 million.
- Capital expenditures were $7.3 million; net cash used in investing was $7.3 million. Year-end debt was $0.9 million, all current equipment loans. The company had no borrowings under its $40 million revolving facility and was compliant with its covenants.
- Gross margin pressure reflected approximately $3.6 million of manufacturing inefficiencies associated with facility consolidations and medical-part requalification. SG&A was $24.1 million, approximately flat year over year.
Fourth-quarter results and comparison
Unaudited Q4 2016 sales were $36.5 million, compared with $33.9 million in Q4 2015. Gross profit was $8.2 million versus $9.0 million; net income was $1.5 million versus $1.7 million; diluted EPS was $0.20 versus $0.23. Thus, quarterly sales increased while gross profit, net income and EPS declined.
Markets and material changes
- Medical sales rose 12.6% for the year, supported by a new five-year customer contract and higher demand; consumer sales rose 24.0%, primarily from molded-fiber protective packaging.
- Aerospace and defense sales fell 20.2%, attributed largely to continued government spending cuts. Electronics sales declined 12.4%, partly reflecting a temporary customer demand spike in 2015.
- Medical represented 44.2% of annual sales; the top ten customers together represented 27.8%. No individual customer exceeded 10%.
- Backlog was approximately $43.7 million as of February 4, 2017, versus $36.5 million a year earlier. Orders can generally be canceled or rescheduled, and backlog includes non-binding blanket orders.
Outlook, risks and other disclosures
- Management expects consolidation-related manufacturing inefficiencies to diminish during 2017. It plans to add manufacturing capacity, further expand the Newburyport facility, and pursue organic growth and potential strategic acquisitions. No specific revenue or earnings guidance is provided.
- Massachusetts consolidations generated approximately $2.1 million of one-time costs; management expects about $1.0 million of annual savings. The consolidations were complete or substantially complete. Part requalification, staffing, delivery and quality disruptions could delay or reduce anticipated benefits.
- Key risks include customer concentration, cyclical end markets, competition and pricing, raw-material and energy costs, dependence on a limited number of suppliers for certain foams, product defects and liability, and execution risks from consolidations or acquisitions. Variable-rate borrowing and credit-agreement covenants are additional risks.
- Operating leases and other listed contractual obligations totaled $1.8 million at year-end, including $0.9 million of equipment-loan principal due within one year. Management said available resources and expected operating cash flow should meet needs for the next 12 months.
- Management and Grant Thornton reported effective internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls. Ordinary-course administrative proceedings were not expected by management to have a material adverse effect.
Important facts for investors to verify
- Whether gross margins recover as consolidation and customer requalification inefficiencies abate, and whether expected annual savings are achieved.
- The sustainability and terms of the new medical contract, plus the quality and conversion of backlog into shipped sales.
- Underlying earnings excluding the $2.1 million settlement gain, and the effect of ongoing restructuring and capital spending.
- Customer and supplier concentration, receivable collection trends, and the impact of cyclical aerospace and defense demand and raw-material costs.
- Remaining debt repayment, revolving-facility covenant headroom, and execution of planned capacity additions and Newburyport expansion.